Rindopepimut clinical trials
How each study uses rindopepimut is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2011 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Celldex Therapeutics (3) · Paul Graham Fisher (1)
Often tested with
Tested in the same studies.
Keyhole limpet hemocyanin (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Temozolomide (1)
Studies
Open first, then newest update. How each study uses rindopepimut is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine GliomasTerminatedPhase 1Paul Graham FisherNCT01058850Written as RindopepimutHow we know
- A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive GlioblastomaCompletedPhase 2Celldex TherapeuticsNCT01498328Written as Rindopepimut (CDX-110) with GM-CSFHow we know
- Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma MultiformeCompletedPhase 2Celldex TherapeuticsNCT00458601Written as CDX-110 with GM-CSFHow we know
- Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed GlioblastomaCompletedPhase 3Celldex TherapeuticsNCT01480479Written as Rindopepimut (CDX-110) with GM-CSFHow we know
Codes
What other systems call rindopepimut · ClinicalTrials.gg INT005830
- MeSH (NLM) C558237rindopepimutConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) K3L4X0501FRINDOPEPIMUTConfirmed FDA, NLM, Wikidata
- Wikidata Q25104603rindopepimutConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C69076RindopepimutOne source FDA
- DrugBank DB05374One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C558237 | rindopepimut | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | K3L4X0501F | RINDOPEPIMUT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q25104603 | rindopepimut | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C69076 | Rindopepimut | One source FDA |
| DrugBank | DB05374 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.